This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar?
by Zacks Equity Research
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -19.05% and 88.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 955% and 160.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health (ELV) to Post Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
Elevance Health's (ELV) third-quarter results are likely to reflect improved premiums and net investment income.
Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -28.57% and 34.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 89.66% and 22.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 8.77% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Biotech Stock Roundup: VRTX's Regulatory Update, TYME Gains on Acquisition & More
by Zacks Equity Research
Regulatory and other updates from Vertex (VRTX) and TYME are a few key highlights from the biotech sector during the past week.
CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 16.67% and 20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Immatics (IMTX): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -5.13% and 459.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.55% and 38.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of 2.38% and 0.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -21.28% and 11.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1.49% and 10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.65% and 11.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Syros (SYRS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Syros (SYRS) stock based on the movements in the options market lately.